Skip to main
VVOS

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics Inc has witnessed substantial revenue growth, with Q3 FY25 revenues reaching $6.8 million, reflecting a 76% year-over-year increase and a 78% sequential rise, driven significantly by the successful integration of the SCN platform. Service revenues exceeded expectations, more than doubling to $4.6 million, anchored by strong performances in sleep testing and treatment-center revenues, highlighting the efficacy of the Vivos System in addressing sleep-disordered breathing. The company's robust projected growth trajectory is supported by expanding market opportunities, particularly in the Asia Pacific region, alongside reported improvements in treatment outcomes for patients with obstructive sleep apnea.

Bears say

Vivos Therapeutics Inc. has experienced a year-over-year revenue decline of 9% in the first half of 2025, driven by its transition to a new sleep center operations model, indicating potential challenges in establishing its new business framework. Despite a slight quarter-over-quarter revenue increase of 27% in Q2 2025, the overall financial performance has been impacted by reduced gross margins, which fell to 55% due to discounting and a changing product/service mix. The company also faces several significant risks, including heightened competition, regulatory challenges, and ongoing operational losses, all contributing to uncertainties regarding its future profitability and growth potential.

Vivos Therapeutics (VVOS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.